Biotech Stocks To Watch Today - November 9th

Key Points

• MarketBeat’s screener highlighted Moderna, AbbVie, Natera, Amgen, Ionis Pharmaceuticals, Regeneron and Edesa Biotech for having the highest recent dollar trading volume among biotech stocks.
• Most of the named stocks rose in Monday trading: Moderna gained $26.01 to $280.20, while Regeneron rose $15.77 to $920.12. Moderna’s price was near its reported 52-week high of $278.28.
• Ionis fell $10.77 to $28.65, near its 52-week low, while Edesa traded more than 70 million shares—far above its average volume of about 1.7 million.

Moderna, AbbVie, Natera, Amgen, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, and Edesa Biotech are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science to develop products or services, such as medicines, vaccines, and diagnostic tools. For investors, these stocks can offer growth potential but may carry higher risk because research, clinical trials, and regulatory approval are uncertain and can take years. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

MRNA traded up $26.01 during trading on Monday, hitting $280.20. The company had a trading volume of 5,613,194 shares, compared to its average volume of 12,616,323. The company has a market capitalization of $111.87 billion, a PE ratio of -39.35 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. Moderna has a one year low of $22.28 and a one year high of $278.28. The firm's 50-day moving average price is $191.85 and its 200 day moving average price is $91.51.

Read Our Latest Research Report on MRNA

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV traded up $1.12 during midday trading on Monday, hitting $292.43. The stock had a trading volume of 1,594,051 shares, compared to its average volume of 6,326,095. The firm has a market cap of $516.90 billion, a price-to-earnings ratio of 50.42, a price-to-earnings-growth ratio of 1.32 and a beta of 0.20. The company has a 50 day simple moving average of $271.98 and a two-hundred day simple moving average of $239.04. AbbVie has a twelve month low of $190.75 and a twelve month high of $302.93.

Read Our Latest Research Report on ABBV

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Shares of NASDAQ:NTRA traded up $13.41 during mid-day trading on Monday, reaching $324.08. 962,671 shares of the stock were exchanged, compared to its average volume of 1,455,236. The stock's 50 day simple moving average is $380.25 and its 200-day simple moving average is $269.68. Natera has a one year low of $181.00 and a one year high of $437.41. The company has a market cap of $46.71 billion, a P/E ratio of -284.83 and a beta of 1.55.

Read Our Latest Research Report on NTRA

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

NASDAQ:AMGN traded up $3.06 during trading hours on Monday, reaching $463.48. 576,362 shares of the stock were exchanged, compared to its average volume of 2,753,596. Amgen has a twelve month low of $312.39 and a twelve month high of $483.99. The firm has a 50 day moving average of $422.43 and a 200 day moving average of $378.19. The stock has a market cap of $250.70 billion, a PE ratio of 26.87, a PEG ratio of 3.21 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20.

Read Our Latest Research Report on AMGN

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

IONS stock traded down $10.77 during midday trading on Monday, hitting $28.65. The company's stock had a trading volume of 8,052,454 shares, compared to its average volume of 2,690,145. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 7.73. Ionis Pharmaceuticals has a twelve month low of $27.75 and a twelve month high of $86.74. The company's fifty day moving average price is $46.80 and its 200 day moving average price is $65.88. The stock has a market capitalization of $4.76 billion, a P/E ratio of -8.29 and a beta of 0.43.

Read Our Latest Research Report on IONS

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Shares of Regeneron Pharmaceuticals stock traded up $15.77 during trading hours on Monday, reaching $920.12. 234,564 shares of the company's stock were exchanged, compared to its average volume of 832,142. The stock has a market cap of $94.73 billion, a P/E ratio of 20.35, a P/E/G ratio of 1.20 and a beta of 0.10. The company has a 50 day moving average of $804.38 and a two-hundred day moving average of $742.81. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $991.73.

Read Our Latest Research Report on REGN

Edesa Biotech (EDSA)

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.

Shares of NASDAQ:EDSA traded up $0.90 during midday trading on Monday, reaching $3.04. The company had a trading volume of 70,201,809 shares, compared to its average volume of 1,709,673. The business's 50 day moving average price is $3.54 and its 200 day moving average price is $5.52. The stock has a market cap of $29.30 million, a PE ratio of -1.81 and a beta of 1.26. Edesa Biotech has a 1-year low of $0.72 and a 1-year high of $20.32.

Read Our Latest Research Report on EDSA

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.